From: Design, synthesis and biological potentials of novel tetrahydroimidazo[1,2-a]pyrimidine derivatives
Human breast cancer cell line MCF-7 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% Control growth | ||||||||||||||||
Molar drug concentrations | ||||||||||||||||
Experiment 1 | Experiment 2 | Experiment 3 | Average values | |||||||||||||
10−7M | 10−6M | 10−5M | 10−4M | 10−7M | 10−6M | 10−5M | 10−4M | 10−7M | 10−6M | 10−5M | 10−4M | 10−7M | 10−6M | 10−5M | 10−4M | |
1 | 106.9 | 101.9 | 100.7 | 38.0 | 106.9 | 97.2 | 90.7 | 38.6 | 102.8 | 106.8 | 92.6 | 41.0 | 105.6 | 102.0 | 94.7 | 39.2 |
3 | 111.3 | 91.2 | 83.4 | 29.3 | 107.9 | 101.8 | 90.2 | 33.2 | 90.1 | 110.2 | 96.3 | 38.6 | 103.1 | 101.1 | 90.0 | 33.7 |
10 | 111.2 | 106.9 | 87.6 | 80.0 | 45.3 | 115.4 | 88.8 | 93.4 | 74.4 | 106.6 | 108.4 | 113.4 | 77.0 | 109.6 | 94.9 | 95.6 |
13 | 101.0 | 104.4 | 84.4 | −1.9 | 107.3 | 107.7 | 92.6 | 1.9 | 102.5 | 105.9 | 91.9 | 16.8 | 103.6 | 106.0 | 89.6 | 5.6 |
15 | 96.6 | 100.8 | 99.0 | 41.7 | 106.8 | 114.1 | 102.6 | 49.0 | 110.1 | 117.3 | 107.4 | 55.3 | 104.5 | 110.8 | 103.0 | 48.7 |
18 | 94.69 | 99.7 | 92.55 | 22.66 | 117.9 | 108.6 | 92.21 | 22.27 | 107 | 113.6 | 105 | 21.09 | 106.5 | 107.3 | 96.59 | 22.01 |
20 | 110.7 | 96.6 | 78.2 | 34.8 | 114.2 | 112.1 | 87.7 | 35.3 | 107.7 | 108.6 | 99.0 | 42.1 | 110.9 | 105.8 | 88.3 | 37.4 |
22 | 102.1 | 107.3 | 91.5 | 46.9 | 99.6 | 103.7 | 91.1 | 48.3 | 104.0 | 111.1 | 104.4 | 46.1 | 101.9 | 107.4 | 95.7 | 47.1 |
23 | 100.2 | 95.4 | 77.2 | −44.5 | 104.0 | 101.5 | 76.8 | −43.1 | 76.3 | 101.6 | 81.4 | −17.1 | 93.5 | 99.5 | 78.5 | −34.9 |
MNP | 105.0 | 97.0 | 99.8 | 86.2 | 101.6 | 108.5 | 90.4 | 89.1 | 102.4 | 64.1 | 90.4 | 81.0 | 103.0 | 89.9 | 93.5 | 85.5 |
ADR | −34.5 | −46.5 | −63.5 | −79.5 | −62 | −49.7 | −67 | −79.3 | 13.69 | −38.2 | −63.6 | −69.9 | −27.6 | −44.8 | −64.7 | −76.2 |